NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

Don't have an account? Subscribe



Rosacea in focus

By Eamonn Brady, MPSI, Whelehans Pharmacies, Mullingar, Co Westmeath - 23rd Sep 2022


Rosacea is an inflammatory skin disease causing facial flushing, redness, papules, pustules and in some cases permanent dilation of small blood vessels (known as telangiectasia). The cheeks, chin, forehead, and nose are usually the worst affected, with the rest of the face mainly unaffected. Rosacea can be temporary in some cases, but is often recurrent or persistent. There are four subtypes of rosacea. It is sometimes referred to as acne rosacea; however, this can cause confusion, as rosacea is unrelated to acne vulgaris. Rosacea is mostly diagnosed in people aged 40-to-59 years and is rare in people aged under 30.


Worldwide estimates of prevalence vary widely from 1-to-22 per cent. It is often referred to as the ‘Curse of the Celts’, as it is especially prevalent in people of Celtic and Irish decent. For example, in a study in the US, 33 per cent of those with rosacea reported at least one parent of Irish ancestry, despite only 15 per cent of the US population being of Irish decent. Despite its association with Celtic people, rosacea also occurs in populations with darker skin tone. Its estimated prevalence in the UK is 10 per cent, and an estimated 15 per cent of the population in Ireland.

The pathophysiology of rosacea is complex and multifactorial; and causes are a mix of genetic and environmental influences.

A genetic cause has not been found; despite this, studies suggest that people with rosacea are four times more likely to have a family history of the disorder than people without the condition.

The immune system also has an influence in causing rosacea. High levels of cathelicidins are present in people with rosacea. Cathelicidins are antimicrobial peptides that are part of the innate immune system that cause neutrophilic infiltration of the dermis and dilation of blood vessels, causing oedema and inflammation.

Ultraviolet (UV) radiation from sunlight has a pro-inflammatory effect, which explains why sunlight exacerbates symptoms of rosacea. UVA light causes collagen denaturation and activates an inflammatory response. UVB light promotes release of fibroblast and vascular growth factors, which increase blood vascularity. Higher levels of matrix metalloproteinases (MMPs), including collagenase and elastase, increase inflammation and are seen in people with rosacea, which may be a factor in causing the thicker and harder skin.

Other factors, including heat or capsaicin in foods, can increase flushing and burning. Increased water loss in the epithelium results in decreased epidermal hydration for people with rosacea, which worsens symptoms as it reduces the skin’s barrier function.

Influence of skin bacteria
People with rosacea have been shown to have higher counts of Staphylococcus epidermidis and the hair follicle mite Demodex folliculorum, which promote inflammation. Noted Irish rosacea expert dermatologist and researcher Prof Frank C Powell, UCD Charles Institute of Dermatology, has noted that the Demodex mites are most plentiful in the same regions of the face that are most commonly affected by rosacea – the cheeks, nose, chin, and forehead – and that large quantities of mites have been found in biopsies of rosacea papules and pustules.

Bacillus oleronius has also been linked to rosacea, probably due to increased inflammatory cytokine production.

Helicobacter pylori (H.pylori), a common bacteria found in the gastrointestinal tract, has been shown to have a higher prevalence in the gastrointestinal tract of rosacea patients. H.pylori increases levels of nitrous oxide in the blood and tissues, which is the reason it seems to increase erythema (red inflamed skin) in rosacea.

Facial redness is the most obvious symptom of rosacea, as well as dry, flaky, sensitive skin that burns or stings when facial creams like sunscreen or make-up are applied. Rosacea increases the risk of blepharitis, sore and inflamed eyes, swelling of facial areas, and can risk development of an enlarged nose (rhinophyma) with prominent pores (sebaceous hyperplasia). The area around the eyes is unaffected, though the eyelids are often affected.

It is more common in women, but tends to be more severe and peaks later in men. Rosacea tends to affect women more on the cheeks and chin, while men are more likely to have rhinophyma. Rosacea can result in self-consciousness and embarrassment that can lead to social anxiety and depression. Therefore, it is important that rosacea is not dismissed as either trivial or a simple cosmetic issue.

Primary symptoms: Erythema, pustules, and telangiectasia
Temporary facial flushing similar to blushing or sunburn in the centre of the face is often the first sign of rosacea. This is due to vasodilation. This erythema (flushing) generally becomes more permanent and noticeable with time, with swelling often developing. Blood tests or skin biopsies are not needed to diagnose; diagnosis is based on physical signs and symptoms. Identifying triggers to be avoided should be part of the diagnosis process. Rosacea diagnosis requires one or more of the primary symptoms, which are:
 Transient erythema, ie, flushing;
 Non-transient erythema;
 Telangiectasia: Image 1;
 Papules or pustules: Image 2.

Secondary symptoms
Secondary features can include a burning or stinging sensation, dry skin, oedema, phymatous changes, ie, thickened skin, lump-like nodules, and enlarged, red, and bumpy nose, known as rhinophyma (Image 3).

Ocular rosacea
Approximately half of people with rosacea have symptoms affecting the eyelids or eyeball (Image 4). Symptoms include watery or bloodshot eyes, dry eyes, burning, stinging or itchy eyes, blurred vision, sensitivity to light, and recurrent styes. Ocular rosacea is also associated with conjunctivitis, anterior blepharitis, including irritation of eyelash bases and eyelid margin, and posterior blepharitis, which affects ducts and eye secretions, and meibomian cysts (small swellings on either the upper or lower eyelid, or on both). Symptoms of more severe ocular rosacea include keratitis, iritis, episcleritis, and scleritis.

Conditions with similar symptoms
Skin conditions with similar symptoms to rosacea include:

Acne vulgaris: New-onset acne vulgaris is uncommon in older populations. If open and closed comedones (blackheads and whiteheads) occur, then acne vulgaris is more likely, as they do not occur with rosacea. People with acne tend to have more greasiness of the skin. Involvement of the chest and back is often a feature of acne, but this is not the case in rosacea.

Contact dermatitis: Irregular distribution and recurrent episodes of blistering with swelling, or red, dry plaques may indicate contact dermatitis.

Seborrhoeic dermatitis: Presents as erythema and scaling, with some itch. Seborrhoeic dermatitis most commonly affects the lateral sides of the nose and the nasolabial folds (skin folds that run from each side of nose to corner of mouth), eyebrows and glabella (area of the forehead above and between the eyebrows).

Rosacea fulminans: Rosacea fulminans occurs more in young women after puberty and resembles rosacea or severe acne, but flushing does not occur.

Steroid rosacea: Due to overuse of topical steroid creams. The symptoms are similar to conventional rosacea, making it difficult to distinguish.

Subtypes of rosacea

The four subtypes are not an indication the condition is worsening, and patients can have more than one subtype at any one time. They are:

Erythematotelangiectatic rosacea (Image 1): Frequent episodes of transient facial erythema (flushing) and non-transient, or persistent erythema. Associated with facial oedema, burning, or stinging and rough or scaly skin.

Papulopustular rosacea (Image 2): Includes ‘whitehead’ pustules and red, swollen bumps, which typically occurs on the cheeks, chin, and forehead and can be mistaken for acne. Facial redness and flushing may appear too, but people with papulopustular rosacea tend to have less flushing.
Phymatous rosacea: Thickening of the skin and uneven surface nodularities on the nose, forehead, chin, ears, and eyelids.
Ocular rosacea (Image 4): Described above.

Non-pharmacological options
There are triggers which may not be the primary cause of rosacea, but may exacerbate symptoms. They should be identified and avoided. Triggers can include sunlight, temperature extremes, wind, stress, spicy foods, hot drinks, alcohol, and some drugs such as topical corticosteroids, vasodilators such as nicotinic acid.

General advice
 Moisturise regularly, especially if skin is dry, ie, non-greasy emollients that reduce moisture loss and reduce roughness.

 Wear sunscreen. Some patients benefit by use of a high-factor sunblock (factor30+) all-year-round.
 Placing ice between cheek and gum can reduce erythema short-term.
 Reduce spicy foods, alcohol, and hot showers.

Ease blepharitis from ocular rosacea with:
 Warm compression and gentle massage of the eyelid margin.
 Cleaning the eyelid with a cotton bud or along the eyelid margin with diluted baby shampoo.

 Avoiding cosmetics around the eye, especially eye-liner.
 Preservative-free ocular tear substitutes are best to treat dry eyes.

Pharmacological treatment
Topical treatments are first choice for mild rosacea and oral treatments should be reserved for moderate-to-severe rosacea. The UK’s Primary Care Dermatology Society (PCDS) published Rosacea: A primary care treatment pathway in 2016. It identified that patients with rosacea often end up on prescribed antibiotics for many years; however, now that very effective non-antibiotic alternatives are available, the PCDS were keen to endorse the use of non-antibiotic treatments to help reduce risk of antibiotic resistance. For example, in the UK, it is estimated that 8 per cent of all antibiotics prescribed are for dermatology indications.

There are many topical rosacea treatments, which include:

Metronidazole cream: Topical metronidazole’s ability to treat rosacea is due to its anti-inflammatory properties instead of its antimicrobial effects. It can be used short-term for a flare-up or longer-term for more persistent cases, or combined with oral medication in persistent or severe rosacea.
Topical metronidazole should be applied to affected areas twice daily for three-to-four months to experience maximum benefit. This benefit can last for three-to-six weeks after treatment, but in some cases can give remission for up to six months after treatment. Side-effects of topical metronidazole can include dry and irritated skin, but side-effects are generally mild.

Azelaic acid: A topical anti-inflammatory used as an alternative to topical metronidazole. It is licenced for the relief of mild-to-moderate papulopustular acne of the face and the treatment of papulopustular rosacea.

Some evidence suggests topical azelaic acid may have the benefit of not contributing to antimicrobial resistance when compared to topical metronidazole. Apply azelaic acid once or twice daily, for three-to-four months for maximum benefit. Some 70-to-80 per cent of cases see symptom improvement to
some degree within three-to-six weeks of commencement.

Side-effects of topical azelaic acid can include mild skin burning, stinging, and irritation, especially on initial use. Tolerance to side-effects usually develops with ongoing use. Wash hands after each application to avoid irritating hands or inadvertently rubbing in the eyes. Avoid alcoholic cleansers, tinctures and astringents, abrasives, and peeling agents when using azelaic acid to minimise irritation.

Comparing topical metronidazole to topical azelaic acid

No major differences in efficacy of topical metronidazole and topical azelaic acid have been noted in studies over the years. When comparing metronidazole to azelaic acid, metronidazole 0.75 per cent gel was less effective than azelaic acid 15 per cent gel (Skinoren) in reducing inflammatory lesions and erythema. Metronidazole 0.75 per cent cream and azelaic acid 20 per cent cream (Skinoren 20 per cent cream, which is licenced in the UK, but not in Ireland) induced significant and near-equal reduction in papules and pustules. Additionally, more satisfaction was reported with azelaic acid.

Topical corticosteroids
Topical corticosteroids should not be used to treat rosacea. While topical corticosteroids can give short-term relief due to vasoconstrictive and anti-inflammatory action, they will aggravate symptoms over the following weeks. This is why topical corticosteroids are known as the ‘Great Impostor’ when it comes to rosacea; as while they reduce inflammation and redness short-term, longterm use of topical corticosteroids actually causes rosacea-like symptoms.

Other topical treatments
Brimonidine gel 0.33 per cent (Mirvaso) is relatively new to the market and aims to reduce redness shorterm in erythematous rosacea. It is more effective in treating flushing, but does not appear to be any more effective than metronidazole or azelaic acid for other rosacea symptoms. The possibility of rebound flushing can limit use of brimonidine gel.

The European Medicine Agency’s (EMA) public assessment report in 2019 for Mirvaso stated that it “has not been systematically investigated” when compared to metronidazole or azelaic acid gel. While it does give relief, its effectiveness compared to more traditional treatments like metronidazole or azelaic acid is less proven, but more studies will help prove its effectiveness.

Ivermectin cream (Soolantra) can improve papulopustular rosacea. Studies show ivermectin cream will produce partial to full clearance of rosacea lesions in 40-to-80 per cent of those with moderate-to-severe symptoms after three months of treatment.

Studies indicated ivermectin is more effective than metronidazole cream and gave improved quality-of life, reduced lesion counts, and less disease severity compared to metronidazole.

Oral rosacea treatments
Oral medicines are reserved for rosacea that is resistant to topical treatments and for more severe rosacea. Non-steroidal anti-inflammatory drugs (NSAIDs) will not cure the condition, but may relieve discomfort (or ‘soreness’) caused by rosacea and moderately ease erythema. However, NSAIDs should in no circumstance be a first-line treatment or a long-term treatment to ease symptoms.
Oral antibiotics
Tetracycline antibiotics interfere with the inflammatory process that causes both acne and rosacea. They reduce rosacea-associated erythema, papules, pustules, and eye symptoms. Tetracycline is effective at doses lower than required for antimicrobial treatment, meaning the clinical benefit is not due to its antimicrobial effect, but through the still unproven theory of its inhibition of MMPs.
MMPs, also called matrixins, are enzymes which function in the extracellular environment of skin cells and degrade both matrix and non-matrix proteins, such as collagen and elastin.
Doxycycline and minocycline are two tetracyclines effective against rosacea. Tetracyclines in lower doses, ie, 50mg daily, are considered as effective as higher doses.

Repeated courses of tetracyclines may be required, but at low doses antimicrobial resistance is not deemed an issue.

Recommended initial treatment regimens are:

 Doxycycline 50mg, once daily, for six-to-12 weeks.

 Minocycline 50mg, once daily, for six-to-12 weeks.

Gastrointestinal side-effects of tetracyclines can include heartburn, nausea, vomiting, and diarrhoea. Photosensitivity, including photo-onycholysis, can occur when taking doxycycline. Photo-onycholysis is a
rare phototoxic reaction, which causes the separation of the nail plate from the nail
bed. Avoid prolonged exposure to UV light from the likes of sunlight when taking doxycycline; sunscreen is advised.

Gastrointestinal adverse effects and photosensitivity are less likely with minocycline compared to doxycycline, though there is an increased risk of hepatitis and drug-induced lupus erythematosus.

Tetracycline antibiotics are teratogenic, so are contraindicated in women who are pregnant or breastfeeding. Oral contraceptives are advised in women of childbearing age.
Doxycycline MR 40mg (Efracea MR 40mg) is licenced in Ireland and the UK for rosacea with papulopustular lesions; it has fewer side-effects without being less effective than doxycycline 100mg.
Oral erythromycin may be prescribed for rosacea as an alternative to oral tetracyclines. Erythromycin is unlicensed for rosacea, but is an effective antibiotic for papulopustular rosacea. Its use can be limited by gastrointestinal disturbance. Erythromycin at a dose of 250mg/day is effective for rosacea when intolerant to tetracyclines or those where tetracyclines are contraindicated, including pregnant women. Clarithromycin is also sometimes used for rosacea where tetracyclines are contraindicated.

Low-dose oral isotretinoin is licensed for acne, not rosacea, but it is prescribed in an unlicensed manner by dermatologists as an alternative if oral antibiotics have been ineffective or not tolerated. The dose used for rosacea is approximately a quarter that used to treat acne, meaning side-effects are minimised; however, the course needs to continue for many months or even longer. There is good evidence to support its use with severe and persistent rosacea and in those with papulopustular and phymatous subtypes of rosacea. It is teratogenic, so female patients should use at least one effective form of contraception for one month before, during, and one month after treatment has ceased.

Isotretinoin and tetracyclines are contraindicated due to a higher risk of benign intracranial hypertension.
Recommended isotretinoin regimen for rosacea is:
 Isotretinoin, 0.1-0.3mg/kg/day for 12 weeks; followed by twice-weekly long-term dosing, if required.
Side-effects of isotretinoin are numerous, but in low doses it is well-tolerated. Side-effects include dry skin, lips, and eyes. Rarely, isotretinoin causes hepatic impairment, elevated serum lipid levels, pancreatitis, and psychiatric events, including depression and suicide.

Drugs to reduce flushing in an unlicensed capacity

Carvedilol, a non-selective beta-blocker with some alpha-blocking activity, may be prescribed to reduce flushing as an unlicensed indication. Carvedilol 6.25mg twice-daily is thought to be the effective dose for flushing in rosacea. As with all beta blockers, carvedilol is contraindicated with asthma, hypotension, or bradycardia.
Clonidine, an alpha2-receptor agonist, is sometimes prescribed in an unlicensed indication for rosacea to reduce flushing. Its effect on facial flushing is questioned by some experts. Low-dose regimes of clonidine are advised, ie, clonidine, 25-to-50mcg daily. Clonidine is contraindicated with severe bradyarrhythmia. It is advised to withdraw clonidine slowly to prevent rebound hypertension.

Calcineurin inhibitors such as tacrolimus ointment and pimecrolimus cream are again unlicensed, but are only thought to give a small reduction in inflammation in severe rosacea.
These unlicensed drugs should only be prescribed as a last resort when traditional licenced treatments have failed and symptoms are so severe that they are affecting the patient’s quality-of-life. They should only be prescribed under specialist dermatologist supervision.

Pharmacological treatment for ocular rosacea

Practice good eyelid hygiene and use ocular lubricants. Pharmacological treatment for ocular rosacea should only be considered after non-pharmacological treatments have been used without success.
Evidence suggests oral tetracyclines (ie, doxycycline) and macrolides (ie, erythromycin) for one-to-three months improves tear film stability and increases meibomian secretions where ocular rosacea is severe.
Topical corticosteroids are best avoided and should only be used for the short-term treatment of very severe inflammation or rosacea keratitis (best under supervision of an ophthalmologist); as the long-term use of topical corticosteroids increases risk of glaucoma and cataracts.

Specialised treatments for rosacea

Persistent telangiectasia that is not improved by conventional topical or oral therapies for rosacea may be treated with vascular laser or intense pulsed light (IPL) treatment, with varying degrees of success in terms of reducing erythema and flushing. If these techniques are unavailable, cautery (use of mild electric current), diathermy (electrosurgery) or sclerotherapy (saline injections) may be beneficial. Where
rosacea causes severe nose deformity (ie, rhinophyma), surgery or carbon dioxide laser may be used by dermatologists or plastic surgeons to reshape the nose.

References available upon request

Disclaimer: Brands mentioned in this article are meant as examples only and not meant as preference to other brands.

Leave a Reply






Latest Issue
The Medical Independent 23rd April 2024

You need to be logged in to access this content. Please login or sign up using the links below.


Most Read